Dr. John Leonard has worked in the biotechnology industry since 1988, with a career focused on the development and commercialization of therapeutic monoclonal antibodies. He held key leadership roles at Idec Pharmaceuticals and Biogen Idec, where he contributed to the successful commercialization of Rituxan, the first therapeutic antibody approved by the FDA, as well as programs leading to the approval of Zevalin and Tysabri. Dr. Leonard currently serves as a Trustee of the UC Riverside Foundation and is a member of the capital campaign committee for the Yosemite Conservancy. He is also the Chief Executive Officer of the John and Elizabeth Leonard Family Foundation, which supports STEM education through grants to faculty and students at two California universities. The foundation also funds community-based programs addressing homelessness and food insecurity and supports local environmental conservation initiatives. In partnership with the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO), the foundation provides research grants to early-career scientists and physicians engaged in basic and translational cancer research.